

Gilles DULUCDirecteur de la Recherche Clinique
et de l'Innovation

Talence, le 13/05/2025

Jeanne PATARDDirectrice adjointe de la Recherche
Clinique et de l'Innovation**Département Promotion Interne****Anne GIMBERT**

Responsable

Tél 05.57.82.04.34

anne.gimbert@chu-bordeaux.fr**Object :** Interventional Clinical Trial's results posting to the European Clinical Trial register (EudraCT) of the European Medicines Agency (EMA).

In accordance of Directive 2001/20/CE


Study Title : MISOBOLD : Prostate cancer hypoxia using BOLD MRI and 18F-FMISO PET imaging**EudraCT Nbr :** 2015-000377-12**Sponsor Nbr :** CHUBX2014/26 / **ANSM Nbr :** 170339A-13**Transitioned study to the Regulation (EU) 536/2014 :** no**Status of the study :** Prematuraly ended study

The study has been prematuraly ended because of a staff turnover through the research staff. As a result the end of the regulatory authorization has been reached. No patient has been recruited in the study and the steering committee decided to close the study.

For the Head of the University Hospital of Bordeaux
and by delegation,
The Director of the Clinical research and Innovation

Gilles DULUC

par délegation Jeanne Patard, directrice adjointe

**DIRECTION GENERALE****12, rue Dubernat - 33404 Talence Cedex - Tél 05 56 79 56 79****www.chu-bordeaux.fr**